CSL Limited

BRSE:CSJ Stock Report

Market Cap: CHF 46.1b

CSL Valuation

Is CSJ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CSJ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: CSJ (CHF73.5) is trading below our estimate of future cash flow value (CHF108.5)

Significantly Below Future Cash Flow Value: CSJ is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CSJ?

Key metric: As CSJ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CSJ. This is calculated by dividing CSJ's market cap by their current revenue.
What is CSJ's PS Ratio?
PS Ratio3.7x
SalesUS$15.80b
Market CapUS$57.71b

Price to Sales Ratio vs Peers

How does CSJ's PS Ratio compare to its peers?

The above table shows the PS ratio for CSJ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.3x
IDIA Idorsia
7.3x18.47%CHF 1.5b
BSLN Basilea Pharmaceutica
3.2x-3.75%CHF 813.6m
GALD Galderma Group
8.4x13.21%CHF 39.5b
LONN Lonza Group
6x10.65%CHF 40.9b
CSJ CSL
3.7x2.97%CHF 80.6b

Price-To-Sales vs Peers: CSJ is good value based on its Price-To-Sales Ratio (3.7x) compared to the peer average (6.2x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does CSJ's PS Ratio compare vs other companies in the European Biotechs Industry?

61 CompaniesPrice / SalesEstimated GrowthMarket Cap
CSJ 3.7xIndustry Avg. 8.5xNo. of Companies61PS01224364860+
61 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CSJ is good value based on its Price-To-Sales Ratio (3.7x) compared to the European Biotechs industry average (8.5x).

Price to Sales Ratio vs Fair Ratio

What is CSJ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CSJ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.7x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CSJ's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CSJ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
CHF 93.41
0%
10.78%CHF 117.35CHF 75.40n/a16
Aug ’27n/a
CHF 78.91
0%
19.06%CHF 112.13CHF 61.20n/a16
Jul ’27CHF 67.60
CHF 78.26
+15.77%
20.82%CHF 112.27CHF 58.75n/a16
Jun ’27n/a
CHF 78.74
0%
20.47%CHF 108.26CHF 56.65n/a16
May ’27n/a
CHF 111.43
0%
11.76%CHF 138.18CHF 86.38n/a16
Apr ’27n/a
CHF 116.37
0%
13.17%CHF 151.48CHF 97.11n/a16
Mar ’27n/a
CHF 116.35
0%
14.31%CHF 147.75CHF 95.76n/a15
Feb ’27n/a
CHF 122.68
0%
11.73%CHF 149.02CHF 96.73n/a16
Jan ’27n/a
CHF 125.05
0%
12.03%CHF 154.90CHF 99.34n/a16
Dec ’26n/a
CHF 128.57
0%
11.10%CHF 156.04CHF 103.15n/a16
Nov ’26n/a
CHF 128.43
0%
12.32%CHF 155.83CHF 99.36n/a16
Oct ’26n/a
CHF 147.75
0%
8.59%CHF 164.28CHF 117.18n/a16
Sep ’26n/a
CHF 148.74
0%
8.13%CHF 163.36CHF 117.98n/a17
Aug ’26n/a
CHF 164.64
0%
7.07%CHF 184.69CHF 132.41n/a17
Jul ’26n/a
CHF 160.40
0%
6.96%CHF 179.19CHF 129.17CHF 67.6017
Jun ’26n/a
CHF 168.60
0%
7.15%CHF 189.77CHF 131.40n/a17
May ’26n/a
CHF 162.73
0%
8.04%CHF 185.11CHF 128.16n/a17
Apr ’26n/a
CHF 177.22
0%
7.44%CHF 199.71CHF 138.28n/a17
Mar ’26n/a
CHF 179.24
0%
7.66%CHF 202.84CHF 140.01n/a16
Feb ’26n/a
CHF 186.41
0%
5.02%CHF 199.74CHF 162.13n/a16
Jan ’26n/a
CHF 190.93
0%
5.95%CHF 209.75CHF 166.95n/a15
Dec ’25n/a
CHF 190.02
0%
6.00%CHF 205.07CHF 163.22n/a15
Nov ’25n/a
CHF 187.52
0%
6.36%CHF 202.77CHF 159.19n/a15
Oct ’25n/a
CHF 182.61
0%
6.43%CHF 202.11CHF 155.45n/a14
Sep ’25n/a
CHF 178.32
0%
9.62%CHF 197.76CHF 128.49n/a15
Aug ’25n/a
CHF 183.09
0%
9.56%CHF 208.67CHF 132.03n/a15
CHF 71.3
Fair Value
3.1% overvalued intrinsic discount
16
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/21 02:18
End of Day Share Price 2026/08/05 00:00
Earnings2026/06/30
Annual Earnings2026/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CSL Limited is covered by 25 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Saul HadassinBarrenjoey Markets Pty Limited
Thomas WakimBell Potter
Lyanne HarrisonBofA Global Research